InvestorsHub Logo

RipperMagoo1

07/23/20 4:24 PM

#1134 RE: Dank02 #1128

Valid points Dank, but somewhat apples to oranges.
- AYTU was the 4th in class for their test and many competitor products out there
- AXIM is 1st in class for their product NeuCovix - new type of test, no competition and with pending patents
- AYTU is showing issues with using non-FDA approved China manufacturing and pushback about efficacy and accuracy
- TBD where AXIM manufacturers but hopefully Peter O'Roarke has the right connections for executing this correctly.
- AYTU is a rapid test just to tell you if you have covid19
- AXIM is a rapid test for testing neutralizing antibodies - a need for those who've been infected or once there is a vaccine.

Who knows how AXIM will market NeuCovix but you're right, it is all hype at this point. However the upside is FAR greater than AYTU. Assuming EUA approval (maybe a big assumption) it's just a matter of how they market and manufactur to scale.

We're not even factoring in all the cancer related compounds and detection products of Axim here. Far too much potential to stay on the sidelines.